(STXS) Stereotaxis, Inc. Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(STXS) Stereotaxis, Inc. Complete Analysis Pack
Visual. Strategic. Downloadable.
This Stereotaxis, Inc. 4P's Marketing Mix Analysis explains the company’s product offering, pricing approach, distribution channels, and promotional tactics in a concise, actionable format; use it to assess positioning and go-to-market strategy. The page contains a real preview/sample of the analysis so you can evaluate style and content before buying—purchase the full version for the complete ready-to-use report.
Product
Genesis RMN and Niobe systems
Genesis RMN and Niobe are Stereotaxis’ core robotic magnetic navigation systems, used to steer catheters and guidewires under imaging for complex heart and vascular procedures. The platform targets precision work in electrophysiology and other interventions, where manual control is harder. Stereotaxis reported 2024 revenue of about $28 million, showing this product line remains its main commercial base.
Odyssey information system
Odyssey is Stereotaxis, Inc.’s real-time information management platform. It manages, controls, records, and securely shares procedural data, and it adds workflow and data connectivity to robotic labs. In catheter labs, faster data access can cut handoffs and support safer, more consistent cases.
Imaging Model S X-ray system
Imaging Model S is Stereotaxis, Inc.'s single-plane X-ray system for robotic interventional operating rooms, built around a c-arm, powered table, motorized boom, and high-definition monitors. It supports precise imaging and procedure visualization, matching the company's FY2025 push to pair robotic navigation with room-ready imaging hardware for complex cardiac cases.
QuikCAS and Vdrive devices
QuikCAS and Vdrive widen Stereotaxis, Inc.'s robotic toolkit by enabling remote catheter control and steadier navigation. QuikCAS supports automated advancement of electrophysiology catheters, while Vdrive is built to improve stability for diagnostic and therapy devices in complex cardiac cases.
These devices matter because Stereotaxis' strategy depends on making robotic procedures more precise and more repeatable. They sit inside a platform used in hospitals worldwide, helping the company sell not just robots, but also the tools that make each procedure work.
- Automates catheter advancement
- Improves device stability
- Extends robotic procedure use
RMT catheters and disposables
Stereotaxis's RMT catheters are the core "Product" offering in its robotic electrophysiology platform, with steerable tip diagnostic and ablation models such as CARTO RMT, CELSIUS RMT, and NAVISTAR RMT, plus irrigated-tip versions for higher lesion delivery.
The company also sells single-use disposables like V-Loop, V-Sono, and V-CAS, which support repeat procedure demand; Stereotaxis reported about $26.6 million in annual revenue in its latest full-year filing.
- Steerable diagnostic and ablation catheters
- Irrigated-tip options available
- Disposable accessories drive recurring use
- Product sales tied to procedure volume
Stereotaxis Product Mix Drives Nearly All Revenue
Stereotaxis, Inc.’s Product mix centers on robotic magnetic navigation systems, imaging, software, and disposable catheters that support complex cardiac cases. FY2025 revenue was about $26.6 million, so Product still drives nearly all sales. The stack is built to boost precision, repeat use, and procedure volume.
| Product | Role |
|---|---|
| Genesis RMN | Core robot |
| Odyssey | Data platform |
| RMT catheters | Recurring use |
What is included in the product
Detailed Word Document
Delivers a concise, company-specific breakdown of Stereotaxis, Inc.’s Product, Price, Place, and Promotion strategy.
Editable Excel File
Condenses Stereotaxis’ 4Ps into a clear snapshot that makes marketing strategy easier to review and communicate.
Reference Sources
Lists primary, reputable sources that let investors verify Stereotaxis’ market, pricing, and competitive claims quickly and traceably.
Place
Direct sales force
Stereotaxis, Inc. sells through its own direct sales force, which lets it sell straight into hospitals and interventional laboratories. This is a fit for high-value medical capital equipment, where long sales cycles, clinical training, and on-site support matter. A direct model also gives Company Name tighter control over pricing, demos, and customer feedback.
Distributor network
Stereotaxis uses distributors to extend reach beyond its direct sales team, so it can serve more hospitals without building a full local team in every market.
This channel helps meet local purchasing, installation, and service needs, which matters in countries where buying rules and support expectations differ by market.
That hybrid model supports international scale while keeping fixed selling costs lower than a fully direct structure, especially for a specialized capital device business.
Sales agents
Sales agents are part of Stereotaxis, Inc.'s go-to-market structure and help represent the portfolio in selected territories. This gives the Company another channel for market access, alongside direct sales and distributors, which matters in a niche medtech market. In FY2025, that channel mix supported reach across international markets without adding a full local sales team in every region.
Domestic market
Stereotaxis serves the U.S. domestic market from Saint Louis, Missouri, and this base keeps it close to major hospital and lab customers. Domestic placement helps the Company maintain ties with U.S. electrophysiology centers, where its robotic systems support complex heart procedures. In its latest filings, the Company continued to report most operating scale from the United States, reinforcing this home market focus.
- U.S. hospitals and labs are core buyers.
- Saint Louis anchors domestic sales support.
- Local presence helps customer relationships.
International markets
Stereotaxis, Inc. serves international markets through a channel mix that combines direct sales and distributors, which helps move robotic interventional systems across borders. That setup supports commercialization outside the U.S. and widens access to its magnetic navigation platforms in Europe, Asia, and other regions. In 2025, this mattered because the company still had a small revenue base, so each added market can move the top line faster.
- Direct plus distributor channels support cross-border sales.
- International reach broadens U.S.-independent access.
- Global demand can scale faster than domestic only.
Stereotaxis’ Hybrid Sales Model Expands Reach Without Heavy Overhead
Stereotaxis, Inc. places its robotic systems through a U.S.-anchored direct force from Saint Louis, plus distributors and agents abroad. That mix fits FY2025’s niche medtech model: long sales cycles, hospital training, and local service all matter. It also lets Company Name reach more electrophysiology labs without a full team in every market.
| Place lever | FY2025 role |
|---|---|
| U.S. direct sales | Saint Louis base |
| Distributors | International reach |
| Sales agents | Local market access |
Get Your Copy
Stereotaxis, Inc. Reference Sources
The preview shown here is the actual Stereotaxis, Inc. 4P's Marketing Mix analysis you’ll receive instantly after purchase—no surprises; it’s the complete, editable document ready for immediate use, covering Product, Price, Place, and Promotion with actionable insights and supporting data.
Promotion
Image-guided precision messaging
Image-guided precision messaging centers on exact catheter and guidewire control under live imaging, which is the core clinical promise of robotic magnetic navigation. It speaks directly to complex interventional cases where millimeter-level accuracy matters and manual handling is harder. For Stereotaxis, Inc., that message supports a higher-value niche and ties promotion to better procedural control.
Workflow and data management messaging
Odyssey gives Stereotaxis, Inc. a clear procedural-data story, not just a robotics story. The platform centers on data management, recording, control, and secure sharing, which helps Stereotaxis speak to full lab workflow needs in 2025. That broader message fits customers who want cleaner procedure data and better coordination across teams.
Robotic interventional room positioning
Imaging Model S reinforces Stereotaxis’ integrated lab offer by showing a complete robotic procedure room, not just a robot. That makes the setup easier for hospital buyers to picture and compare, which can lift deal quality and shorten sales cycles. In 2025, Stereotaxis kept pushing this full-environment story as part of its capital equipment and recurring robotics platform.
Strategic alliance with Osypka AG
Stereotaxis, Inc. announced a joint development alliance with Osypka AG to create a magnetic ablation catheter for use with Stereotaxis robotic technology. The move supports pipeline innovation in the Product and Promotion parts of the 4P mix, and it fits a market where global cardiac ablation device demand is measured in the billions. Partnerships like this can help speed development and broaden clinical reach.
- Joint development with Osypka AG
- Magnetic ablation catheter focus
- Supports pipeline innovation
Portfolio selling across capital and disposable products
Stereotaxis sells a linked portfolio of capital systems, catheters, and accessories, so a single system win can lead to repeat disposable use. That mix keeps the brand present across different procedures and helps widen the installed base’s pull-through. It also supports recurring revenue once the robot is in place.
- One sale can drive repeat catheter use
- Systems anchor long-term account access
- Accessories keep the brand in every case
Stereotaxis Sells Precision, Workflow, and Pipeline Depth
Stereotaxis, Inc. promotes robotic magnetic navigation as millimeter-level control for hard interventional cases, so the message is clinical precision, not just automation. Odyssey adds a data and workflow angle, while Imaging Model S makes the full robotic lab easier for buyers to see. The Osypka AG alliance also signals pipeline depth in magnetic ablation.
| Promotion point | Signal |
|---|---|
| Clinical precision | Millimeter-level control |
| Workflow story | Odyssey data platform |
| Buyer framing | Imaging Model S |
| Pipeline message | Osypka AG alliance |
Price
No public list prices
Stereotaxis does not publicly post standard list prices for its robotic systems, so buyers must get quotes through direct sales talks. This is normal in enterprise medical equipment, where deal size, service, install scope, and hospital volume can change the final price. The model also fits a high-touch selling process, since capital medtech contracts are often negotiated case by case.
Quoted capital equipment pricing
Genesis RMN, Niobe, and Imaging Model S are capital products, so Stereotaxis, Inc. usually prices them by quote rather than list price. Final deal value depends on system configuration, software, install scope, and customer workflow needs. That makes pricing variable, with each hospital or lab getting a tailored package.
Separate disposable pricing
Stereotaxis, Inc. prices catheters, accessories, and disposable components separately from its capital systems, so the Company can set 3 recurring-use price points instead of one bundled fee. That model supports post-install revenue, because each procedure can drive new disposable sales after the robot is in place. In 2025, that mix mattered because recurring sales helped offset the lumpy, higher-ticket capital system cycle.
Negotiated hospital sales
Stereotaxis, Inc. sells to hospitals and interventional labs through negotiated deals, so price is rarely a fixed sticker. Large device buys often bundle system terms, service, training, and timing, which makes pricing an account-level decision rather than a simple unit sale.
- Negotiated contracts shape final price.
- Buyers seek tailored terms.
- Service and support affect economics.
Portfolio-based value pricing
Stereotaxis, Inc. uses a portfolio of robotics, imaging, software, and disposables, so price is tied to clinical value and workflow gains, not just hardware cost. That mix supports premium positioning because the system, software, and recurring disposables together drive a hospital’s long-term economics.
- Portfolio mix supports value-based pricing
- Recurring disposables lift lifetime revenue
- Premium tied to clinical outcomes
Stereotaxis Pricing Mix Boosts Long-Term Revenue
Stereotaxis, Inc. uses quote-based pricing for Genesis RMN, Niobe, and Imaging Model S, so final price depends on config, install scope, and service terms. In 2025, that model helped the Company pair lumpy capital deals with recurring disposable sales, which gives each system more long-term revenue.
| Price driver | 2025 impact |
|---|---|
| Capital systems | Quoted case by case |
| Disposables | Recurring post-install sales |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.